@Article{Danilau2017,
journal="Clinical and Experimental Hepatology",
issn="2392-1099",
volume="3",
number="3",
year="2017",
title="Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus",
abstract=" Aim of the study  is to evaluate real-world efficacy of the ombitasvir/ paritaprevir/ ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype.    Material and methods:   The study included 27 patients according to inclusion criteria. Main laboratory studies were performed in all patients at the baseline and during the treatment.    Results:   Efficacy of the antiviral therapy was assessed by measuring the SVR12 and the SVR24 along with measuring of viral load during the treatment. The SVR12 and SVR24 rate was 100% (27/27).    Discussion : The results of the treatment were comparable to the results of pivotal, large-scale, randomized clinical trials. There were no serious adverse events during the treatment.",
author="Danilau, Dzmitry
and Malich, Nadzeya
and Litvinchuk, Dzmitry
and Karpov, Igor",
pages="164--168",
doi="10.5114/ceh.2017.70281",
url="http://dx.doi.org/10.5114/ceh.2017.70281"
}